Osaka Bio Headquarters 2025

Innovation for Life Science

OSAKA BIO HEADQUARTERS

About Us

OSAKA BIO HEADQUARTER

Osaka Bio Headquarters is a unified initiative of industry, academia, and government in Osaka, aiming to further advance the health and medical industries within the prefecture.

Vision

Transforming Osaka into a global cluster for health and medical industries

Leveraging the strengths of industry, academia, and government collaboration in the field of life science, we aim to drive innovation in areas such as pharmaceuticals, medical devices, regenerative medicine products, and scientific evidence-based health-related products and services. Our goal is to position Osaka as a key growth engine for Japan, supporting and leading the nation's future as one of the two economic hubs in Japan, so that we can aim for further development in health and medical industries.

Member Organizations

Ibaraki City
National Institutes of Biomedical Innovation, Health and Nutrition (NIBN)
University Public Corporation Osaka
Osaka City
Osaka Chamber of Commerce and Industry
The University of Osaka
Osaka Prefectural Government
Kansai Pharmaceutical Industries Association
Kansai Bureau of Economy, Trade and Industry
NPO Kinki Bio-Industry Development Organization
National Cerebral and Cardiovascular Center (NCVC)
Saito (International Culture Park City) Development Promotion Council
Senri Life Science Foundation
Urban Innovation Institute
Organization for Small & Medium Enterprises and Regional Innovation, JAPAN
Japan Agency for Medical Research and Development (AMED)
Bio-Sight Capital inc.
RIKEN

History

Around 1650 (Edo Period)
Osaka, in particular the neighborhood of Dosho-machi had a monopoly on the distribution of medicines and it was referred to as the “City of Medicine”.

Around 1975
The University of Osaka President Yuichi Yamamura (at that time) announced his desire to make the Hokusetsu region in northern Osaka a global hub for life sciences.

July 1977
National Cardiovascular Center (currently National Cerebral and Cardiovascular Center) (Suita City) was established

April 1993
The University of Osaka Faculty of Medicine and Hospital relocated from Nakanoshima in Osaka City to the current location (Suita Campus) that was newly constructed. It was integrated with the Research Institute for Microbial Diseases Hospital.

April 2004
Opening of Saito Life Science Park

April 2005
National Institute of Biomedical Innovation (currently National Institutes of Biomedical Innovation, Health and Nutrition) was established (Saito, Ibaraki City)

September 2008
Osaka Bio Headquarters was established
“Osaka Bio Strategy” was formulated at the “Osaka Bio Strategy Promotion Council” organized by industry, academia and government

October 2013
Pharmaceuticals and Medical Devices Agency (PMDA) Kansai Branch was established (Kita-ku, Osaka City)

April 2015
Japan Agency for Medical Research and Development (AMED) Department of Innovative Drug Discovery and Development West Japan head office was established (Kita-ku, Osaka City)

July 2015
Name of former Suita switching yard site and surrounding area (medical cluster) was decided as “Northern Osaka Health and Biomedical Innovation Town (also known as “KENTO”)”

March 2018
With the completion of the Osaka Bio Strategy, initiatives for 10 years summarized Osaka Growth Strategy has newly designated the health and medical-related industry sector as a priority area, and the strategy defines the formation of a world-class cluster in this sector as a key direction to aim for.

July 2019
National Cerebral and Cardiovascular Center was relocated to KENTO

September 2022
Japan Agency for Medical Research and Development (AMED) Department of Innovative Drug Discovery and Development West Japan head office was relocated to Chuo-ku, Osaka City

March 2023
National Institute of Health and Nutrition under the National Institutes of Biomedical Innovation, Health and Nutrition was relocated to KENTO from Shinjuku, Tokyo

June 2024
Grand opening of Nakanoshima Qross

December 2024
Pharmaceuticals and Medical Devices Agency (PMDA) Kansai Branch was relocated to Nakanoshima Qross

OSAKA BIO HEADQUARTERS

Osaka Bio Headquarters President AKIRA Shizuo

Osaka has flourished since the Edo Period as the “City of Medicine” due to its location as the center of the pharmaceuticals trade. Today, it remains a home to a cluster of outstanding universities, research institutions, and pharmaceutical companies in the field of life science.
In addition to these strengths, Osaka has moved to promote the life science industry, and established the “Osaka Bio Headquarters” and “Osaka Bio Strategy Promotion Council” in 2008. This was due to the vision of the late Yuichi Yamamura, former president of The University of Osaka, who announced his desire to make the Hokusetsu region in northern Osaka a global hub for life sciences. Industry, academia, and government are now working together further develop the sites for Saito, KENTO, and Nakanoshima Qross and promote initiatives such as supporting the overseas expansion of life science companies in Osaka.
2025 is the year of the Expo. The theme of the Osaka/Kansai Expo, “Designing Future Society for Our Lives”, is highly compatible with the field of life science. People from all over the world will gather in Osaka, so we will take this opportunity to aim for further advances in the life science industry of Osaka, based on the slogan of “Transforming Osaka into a global cluster for health and medical industries” as we at Osaka Bio Headquarters aim to become the leader in our field.
We hope that you will keep an eye on the future activities of Osaka Bio Headquarters and thank you for the support.

A cluster of universities and research institutions related to life science in Osaka

North Osaka is a magnet for many outstanding universities and research institutions in the field of life science, and areas such as Saito and Dosho-machi feature a cluster of pharmaceutical companies.

(1)-1 The University of Osaka
2 Research Institute for Microbial Diseases (RIMD)
3 Immunology Frontier Research Center (IFReC), The University of Osaka (IFReC)
4 Institute for Protein Research, The University of Osaka (IPR)
5 The University of Osaka Hospital

(2)-1 Osaka Metropolitan University
2 Osaka Metropolitan University Center for Health Science Innovation
3 Osaka International Research Center for Infectious Diseases (OIRCID)
4 Osaka Metropolitan University Research Institute for Drug Discovery Sciences
5 Osaka Metropolitan University BioMedical Forum
6 Osaka Metropolitan University Hospital Center for Clinical Research and Innovation:CCRI

(3) National Institute of Biomedical Innovation, Health and Nutrition (NIBN)
• National Institute of Biomedical Innovation
• National Institute of Health and Nutrition

(4) National Cerebral and Cardiovascular Center (NCVC)
(5) AIST Kansai, the National Institute of Agency Industrial Science and Technology (AIST)
(6) Japan Agency for Medical Research and Development (AMED)
(7) Pharmaceuticals and Medical Devices Agency (PMDA), Kansai Branch



A center for the practical application and industrialization of future medicine based on regenerative medicine

Nakanoshima Qross

Nakanoshima Qross is a unique hub for the industrialization of future medicine, where medical institutions, companies, startups, support organizations, etc. come together under one roof. The facility aims to promote the industrialization of cutting-edge “future medicine” that is in line with future advances in medical technology, such as genomic medicine, artificial intelligence (AI), and the IoT, based on regenerative medicine, as well as to promote international contributions through the provision of “future medicine” to patients both in Japan and overseas.

Provided by: General Incorporated Foundation for the Organization of Future Medicine

We enable diverse human resources from around the world to gather and connect with the latest information.

Creation
Driving the creation of future medecine by connecting people with information

Future Medicine R&D Center

A composite research and developmet facility designed to meet a variety of research and development needs

- Liaison Office
- Open Inovation Labs
- Incubation Labs

Practice
Driving the practice of future medecine through leading-edge medicine, and other intiatives

Future Medicine Medical Center

Practicing composite medicine founded on collaboration with Future Medecine Medical Center

- Hospital
- Clinic
- Advanced Medical Checkup Center

Sharing
Sharing future medecine through events, international Academic conferences and meetings etc.

Nakanoshima International Forum

An exchange-focused facility providing open space for collaboration with other nearby facilities

- Conference Center
- Spaces for exchange, co-creation, and dissemination (Qrossover Lounge “YUME”)

Mitsui Link Lab Nakanoshima

Well-equipped with rental wet labs, shared wet labs with experimental devices, and common areas such as offices and meeting rooms. A lounge is available for use by tenants, and we promote active communication as a center of open innovation.

CiRA Foundation



The new “my iPS®” project in Nakanoshima, which supplements our main activities in Kyoto

We provide iPS cells and related technology to research institutions and companies at a reasonable price. We have established a new research facility in Nakanoshima, where we collaborate with companies to conduct joint research into developing closed-type automatic cell culture equipment for the goal of reducing manufacturing costs.

Qrossover Lounge “YUME”

We offer a place for interaction, where academia, start-ups, companies, and medical institutions, as well as local citizens, can communicate about future medicine such as regenerative medicine. It is comprised of an information space, co-creation lounge, and studio. The information space can be freely used by anybody.

Pharmaceuticals and Medical Devices Agency (PMDA), Kansai Branch

PMDA is actively promoting the practical application of pharmaceuticals, medical devices, and regenerative medical products by providing consultations and GMP compliance inspection mainly to companies and academia in the Kansai region.
We look forward to welcoming more representatives from start-ups and academia, given their limited interaction with PMDA in the past.

An open innovation hub for healthcare and medicine

Northern Osaka Health and Biomedical Innovation Town (KENTO)

KENTO
健都

At Northern Osaka Health and Biomedical Innovation Town (also known as “KENTO”), research institutions and companies in the field of health and medicine gather and promote open innovation.
By establishing places where citizens can participate in field trials, such as station shopping centers and athletic parks, we promote urban development where locals can participate in the creation of new lifestyles, as well as create a new medical and healthcare industry.

Industry, academia, government, and local citizens working together on urban development with a focus on health and medicine

Health-related companies and facilities cluster around the National Cerebral and Cardiovascular Center and National Institutes of Biomedical Innovation, Health and Nutrition. We promote a virtuous cycle of creating new lifestyles and a new health care industry.



(Reproduced from the KENTO portal site with permission)

Efforts of local companies

AIR WATER INC.

Air Water in KENTO, a site for experience, demonstration, and co-creation in the field of wellness, has an space for exhibiting health care devices on its first floor. Local residents and other visitors can try out the AGEs sensor, which measures substances that cause aging and fatigue, and the TANO exercise game, where your whole body becomes a game controller by standing in front of a sensor. This provides measurement data as well as user opinions that can be adopted to make improvements. The site also links with other companies and the local community to hold health-related events, such as music therapy events and exercise classes. Air Water in KENTO strives to be a place where local residents and those involved in the field of wellness can visit anytime to create, develop, and transmit.

Protosera Inc.

Protosera, Inc. has R&D facilities and a clinical laboratory in KENTO and offers testing services based on its unique research and development. It provides clinical testing for health diagnosis, such as for its own ProtoKey® colorectal cancer and pancreatic cancer risk test and Hepa*Sign*™ liver disease (fatty liver, liver cancer, cirrhosis) risk test products. At its R&D facilities, Protosera links with research institutions around the country, including KENTO, to work on efforts such as discovering new biomarkers for disease prevention and researching disease risk prediction, based on original peptidomic analysis technology. At the clinical laboratory, the company links with the medical institutions of KENTO and local residents based on the results of those efforts to raise awareness on cancer screening and popularize cancer risk testing.

Turnkey Lab KENTO

The KENTO Turn Key Lab is a in a P2/BSL2 environment, which offers equipment and devices for cell culture and genetic analysis, so research can be started immediately with low initial investment. The facility has full-time staff who support day-to-day research with routine work and device maintenance. In addition to the experiment space, the facility offers a salon, meeting room, and drink corner, to ensure a comfortable working space. It also periodically holds seminars, which means it can be used as a place of learning to assist research, as well as a place to offer opportunities for mutual exchange. In addition to those involved with bio-related venture companies, universities, and research laboratories, it is utilized by people in a wide range of industries, such as the manufacturing of industrial parts, electronic components, and devices, as well as material manufacturing.

Tax incentive

KENTO Innovation Park is a designated Special Zone for Growing Industries

Prefectural tax breaks are offered to businesses in fields such as life science that are located in designated areas.
*Conditions apply. Contact Life Sciences Industry Division of Osaka Prefectural Government for details.

An R&D hub for drug discovery in the hills of Minoh and Ibaraki

Saito Life Science Park

彩都 みどりとみらいのみえる丘

Saito Life Science Park, a symbolic zone of Saito, features a major cluster of facilities in life science fields such as biotech and pharmaceuticals. There, companies and research institutions such as the National Institute of Biomedical Innovation link with startups in the incubation facility to collaborate on innovation.

Leading drug discovery in Japan with a wide variety of functions!

National Institute of Biomedical Innovation

NIBN 国立研究開発法人 医薬基盤・健康・栄養研究所 National Institutes of Biomedical Innovation, Health and Nutrition

The National Institute of Biomedical Innovation is a research institution born out of the Osaka branch of the National Institute of Health Sciences, which integrates segments of the National Institute of Infectious Diseases and the Pharmaceuticals and Medical Devices Agency.
By collaborating with nearby The University of Osaka and medical institutions in Osaka Prefecture, the institute acts as a hub for research and development into intractable and rare diseases that are difficult for private companies to tackle, based on the goal of "curing the uncurable". It shares research results from Osaka to the world, in order to give hope to those struggling with disease.

Saito Bio Incubation facility

Bio-Sight Capital

Bio-Sight Capital inc. has been managing and administering the biotech and life science incubation facility at Saito for more than 20 years. As an advanced R&D hub* that develops next-generation technologies, it has hosted about 100 companies, which has led to numerous successful launches of drugs and devices, as well as IPOs and M&As, via its industry and academia network that includes The University of Osaka and National Institutes of Biomedical Innovation, Health and Nutrition. *Supports P2 and allows animal experimentation
The hub will continue to provide an environment where startups can focus on business growth and R&D activities by providing long-term support and relationship building from their inception to their graduation from incubation facilities.

Saito Bio Incubator

An incubation facility for startups including spin-offs from universities

Labs Approx. 67, 138m² 32rooms+1floor

Saito Bio HillsCenter

An incubation facility for a variety of companies in the field of biological- and life sciences

Labs Approx. 77m² 9rooms

Saito Bio Innovation Center

An incubation facility targeted at companies cultivating new business activities

Labs Approx. 70m² 18rooms+1floor

Shared device room with centrifuges and deep freezers available for use by tenants

Periodically exchanging information and holding networking events with companies inside the facility, companies around Saito, and research institutions

Efforts of local companies

Scent Science International Co., Ltd.

Hibernating animals have the ability to protect themselves from hypothermia and bradycardia, which would be fatal to normal organisms. The idea of uncovering this ability and applying it to medicine has long been a dream. However, significant obstacles to its realization remained, and the lack of a clear path toward the goal persisted. Scent Science International Co., Ltd. has specialized in researching and developing functional odor molecules. Our team has harnessed this knowledge to successfully develop innovative odor molecules—the first of their kind in the world—that stimulate the protective center in the brainstem via sensory nerve receptors to induce artificial hibernation/life-protective state. The therapeutic effects of these molecules have also been confirmed in a variety of emergency disease models, including myocardial infarction, cerebral infarction, and acute respiratory distress syndrome. We are working diligently with partners to expedite the launch of the world's first artificial hibernation therapy to market.

A hamster in which a state of hibernation has been induced by olfactory stimulation

GeneDesign,Inc.

Ajinomoto BIO•PHARMA SERVICES

As a member of the Ajinomoto Group, GeneDesign,Inc. actively pursues research and development at Saito area, for aiming to contribute to human health through contract manufacturing and development of oligonucleotides for pharmaceutical drugs. We have established the trust relationship with pharmaceutical companies and academia as an indispensable partner by refining solid-phase synthesis technology and boldly tackling the demands of complex oligonucleotides. In 2024, we achieved the development and commercialization of a high-quality, high-efficiency synthesis method for long-chain RNA, which had previously been considered technically challenging, thereby providing solutions to the challenges faced by researchers. We will continue to untiringly strive to take on new challenges and open up new possibilities in the field of pharmaceutical development.

Matching assistance for innovations

EU-Japan Biotech & Pharma Partnering Conference

To assist the overseas expansion of small to medium sized companies and startups, we hold the EU-Japan Biotech & Pharma Partnering Conference together with the EU-Japan Centre for industrial Cooperation to help partner Japanese companies with European companies.

Highlights of 2024

Number of companies participating	Number of meetings	Number of pitched companies	Number of companies exhibiting posters	Number of countries participating
159	302	38	49	22

Held by

大阪府 Osaka Prefectural Government

EU-Japan Centre for Industrial Cooperation 日欧産業協力センター

enterprise europe network — Business Support on Your Doorstep

Osaka Biotech & Pharma Networking Event

We hold the Osaka Biotech & Pharma Networking Event for partnering with companies interested in Japan, which is recommended by regional governments and state governments in overseas regions with robust life science industries.

Highlights of 2024

Number of companies participating	Number of participants	Number of meetings	Number of cooperating groups (regional governments overseas, etc.)
75	102	56	5

Government of Ontario
Government of Quebec
Scottish Development International
Invest Northern Ireland
Government of Wales

The unique research seeds of Kansai gather here!

This event enables researchers in Kansai to announce research seeds that may lead to opportunities for joint research and partnering with other researchers and enterprises.

Highlights of 2024

Themes

Regenerative medicine, gene therapy, peptide drug creation

Presenters

13

Participating research institutes (in no particular order)

The University of Osaka / Osaka Metropolitan University
Kansai Medical University
National Institute of Biomedical Innovation, Health and Nutrition
Kobe University RIKEN
Kyoto University
Center for iPS Cell Research and Application, Kyoto University (CiRA)
Kyoto Pharmaceutical University

International cooperation and overseas expansion for innovations

BioM (Germany)

A non-profit organization based in Munich, Bavaria that administers the Munich biotech cluster and manages a biotech related network.

bioXclusters

A joint cluster spanning four European countries, which aims to enhance the competitiveness of and spur growth at small to medium-sized European companies in the field of life science.

LYONBIOPOLE (France)

A medical cluster in the Auvergne Rhône-Alpes Region, based in the city of Lyon. Comprised of companies and research centers (university hospitals, universities and foundations).

Biocat (Spain)

An organization comprising a bioscience cluster in the Catalonia Region, which aims to support companies, research groups, hospitals, and universities.

bioPmed (Italy)

A regional innovation cluster in the Piemonte Region that specializes in life science and health care. Includes approximately 100 companies.

POM Limburg (Belgium)

A cluster based in Hasselt, Limbrug Province in the Flanders Region. This non-profit organization operates a major hub (Health Campus Limbrug) representing the Flanders Region where there is a cluster of life science related facilities such as hospitals, universities, and research institutions.

Exhibition business

Our exhibition business showcases the potential of Osaka, improves recognition, and creates business opportunities by exhibiting at and participating in exhibitions and business meetings in Japan and overseas, as well as helping other organizations participate in exhibitions.

BIO International Convention

We participate in BIO International Convention, the largest partnering event in the world, which is held in the United States in June, where we promote ourselves to various overseas clusters. From 2025, we will be exhibiting a booth to further promote the potential of Osaka.

BIO Europe

We will participate in BIO Europe, a partnering event held in Europe in October and November, to showcase the potential of Osaka.

Bio Japan

At the largest partnering event in Asia, to be held at Pacifico Yokohama in Kanagawa in October, we will exhibit a booth to showcase the potential of Osaka and assist the exhibits of companies in Osaka.

Japan Health

We will exhibit a booth to showcase the potential of Osaka at the first international exhibition on themes such as medical devices, health care, and regenerative medicine, held in Japan for the first time in June, 2025 to coincide with Expo 2025 in Osaka, Kansai.

Organizations

We have world-leading universities and research institutions and aim to leverage this strength to create a global cluster

The University of Osaka

大阪大学
THE UNIVERSITY OF OSAKA

The University of Osaka is one of Japan's leading universities and renowned as an academic institution strong in biomedical sciences, especially immunological research. The University of Osaka has produced many researchers. The University of Osaka seeks to create new social value by promoting cooperation and collaboration between industry, government, and academia (=industry-university co-creation) from the fundamental research phase.

- Establishing Joint Research Chairs, Joint Research Division and Research Alliance Laboratories, and concluding comprehensive partnership agreements
- Promoting technology transfer of intellectual properties
- Providing support to university-originated venture businesses

1-1 Yamada-oka, Suita City, Osaka
+81-6-6877-5111

Research Institute for Microbial Diseases (RIMD)

RIMD
Research Institute for Microbial Diseases
大阪大学微生物病研究所

Research Institute for Microbial Diseases (RIMD) is the world's foremost institute in the fields of medicine and biology including microbiology, immunology, and oncology. Currently, in addition to these research fields, we are developing research in various fields such as genetic engineering and genome analysis.

Office for Research Promotion
1-1 Yamada-oka, Suita City, Osaka
+81-6-6877-5111

Immunology Frontier Research Center (IFReC), The University of Osaka

WPI Osaka University
iFReC

IFReC is an international immunology research center established in 2007 as part of the Japanese government's WPI program. We are accelerating cutting-edge basic research incorporating bioimaging and bioinformatics, and its application to human medicine. In addition, as a hub for joint research, we are promoting the construction of an open innovation laboratory.

Research Planning and Management Office
3-1 Yamada-oka, Suita City, Osaka
+81-6-6879-4273

Institute for Protein Research, The University of Osaka (IPR)

INSTITUTE for PROTEIN RESEARCH

Institute for Protein Research, the University of Osaka conducts fundamental research on proteins by integrating experimental and computational sciences. It has established an advanced research framework as a center of joint-use and collaborative research, facilitating shared use of large-scale equipment (Synchrotron Beamlines, NMR, and Cryo-EM), developing and maintaining the Protein Data Bank (PDB), organizing Protein Research Seminars, and promoting protein data science.

3-2 Yamada-oka, Suita City, Osaka
+81-6-6877-5111

The University of Osaka Hospital

病院

The University of Osaka Hospital is a hospital for advanced medical development, and its philosophy is to provide high-quality medical care services and contribute to fostering medical professionals and medical development. The University of Osaka Hospital as a clinical research, core hospital, aims to contribute to the future development of the medical and pharmaceutical industry in Japan by taking advantage of various measures designed for national strategic special zones, including those for "pharmaceutical affairs strategic consultation" and "accelerated development of innovative pharmaceuticals."

2-15 Yamada-oka, Suita City, Osaka
+81-6-6879-5111

Osaka Metropolitan University

大阪公立大学
Osaka Metropolitan University

Osaka City University and Osaka Prefecture University merged in 2022 to form Osaka Metropolitan University, the largest public university in Japan, comprising 12 faculties and 15 graduate schools. The university conducts interdisciplinary research in the life sciences, leveraging its strengths in medicine, veterinary science (the only program of its kind in Kansai), engineering, science, and a wide range of social sciences. In 2026, the Graduate School of Drug Discovery Sciences will be inaugurated, further advancing our academic and research endeavors.

Osaka Metropolitan University Office for Co-Creation Initiatives
1-1 Gakuen-cho, Naka-ku, Sakai City, Osaka
+81-72-254-9128

Osaka Metropolitan University Center for Health Science Innovation

In addition to creating innovation in the domain of a more familiar “health and health science” with a focus on the medicine and science of fatigue/anti-fatigue, the Center for Health Science Innovation pursues activities to help people experience creating innovation in the domain of “more active health management” with a focus on sports science and health science.

https://www.omu.ac.jp/orp/chsi/
+81-6-6485-0288
gr-knky-chsi@omu.ac.jp

Osaka International Research Center for Infectious Diseases（OIRCID）

Osaka International Research Center for Infectious Diseases (OIRCID) recognizes infectious diseases as social issues and promotes interdisciplinary “macro-infectious disease studies” through collaboration with experts across diverse fields, governments, and industry, leveraging the integrated academic expertise of Osaka Metropolitan University.
With the goal of developing a “resilient city against infectious diseases,” OIRCID is implementing practical solutions to address the “metropolitan health”, challenges faced by the Osaka Metropolis.

https://www.omu.ac.jp/oircid/

Osaka Metropolitan University Research Institute for Drug Discovery Sciences

This is a center that engages in interdisciplinary research related to drug discovery. We are engaged in research to create new drug candidate compounds, including biopharmaceuticals, which constitute a large portion of new drugs, as well as traditional small molecule drugs. By utilizing nanoscale polymers in drug delivery systems, we aim to provide the ultimate treatment without side effects by precisely delivering encapsulated drugs to the disease site.

Prof. Takashi Inui, Graduate School of Agriculture
1-1 Gakuen-cho, Naka-ku, Sakai City, Osaka
+81-72-254-9473

Osaka Metropolitan University BioMedical Forum

The BioMedical Forum, comprising three research laboratories and three centers, which are all deeply involved in key R&D processes up to the preclinical stage of drug development, plans and proposes biomedical strategies and promotes mutual collaboration between members.

URA Center
1-1 Gakuen-cho, Naka-ku, Sakai City, Osaka
+81-72-254-9128

Osaka Metropolitan University Hospital Center for Clinical Research and Innovation：CCRI

Our center is dedicated to ensuring the integrity of clinical research, actively supporting its advancement, and promoting industry-academia collaboration to contribute to medical progress and benefit society at large. In clinical trials, we strive to obtain high-quality data and provide a support system to ensure smooth and appropriate execution. Our hospital is capable of conducting clinical trials across all medical departments.

Abeno Medix 6F, 1-2-7 Asahimachi,
Abeno-ku, Osaka

National Institute of Biomedical Innovation, Health and Nutrition (NIBN)

NIBN promotes common and private researches and developments that contribute to the development of pharmaceuticals, medical devices, biological resources, etc., with the aim of improving pharmaceutical technologies and medical device technologies. It also conducts surveys and researches on health and nutrition, as well as services based on Health Promotion Act, with the aim of improving public health and national health.

7-6-8 Saito-Asagi, Ibaraki City, Osaka
+81-72-641-9811(Main)

National Cerebral and Cardiovascular Center (NCVC)

The National Cerebral and Cardiovascular Center (NCVC) was established as a national center for advanced and specialized medical care and research, with the mission to understand and control cerebral and cardiovascular diseases in order to protect public health in accordance with national medical policy. Specialists - both medical practitioners and researchers - in the fields of cardiac and cerebrovascular diseases and businesses work together to improve treatment outcomes, develop new technologies and train specialized medical personnel.

6-1 Kishibe-Shimmachi, Suita Citym Osaka
+81-6-6170-1070(Main)

AIST Kansai, the National Institute of Agency Industrial Science and Technology (AIST)

The Molecular Biosystems Research Institute of the AIST Kansai aims to implement biotechnology into society through research and development of measurement platforms and standards, and the exploration, evaluation and application of functional biomolecules. In collaboration with government agencies and private sectors, we promote the development of diagnostic and testing devices such as ultra-fast PCR, improved biomanufacturing through genome editing, and the development and environmental performance evaluation of biodegradable plastics.

Industry-academia-government Collaboration Promotion Office
1-8-31 Midorigaoka, Ikeda City, Osaka
+81-72-751-9606

Institutions assisting drug creation, etc.

Department of Innovative Drug Discovery and Development Japan Agency for Medical Research and Development (AMED)

We provide technical support via the Drug Discovery Support Network, which consists of AMED, RIKEN, the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), and The National Institute of Advanced Industrial Science and Technology (AIST), to enable the commercialization of outstanding potential new drugs owned by researchers at universities and other institutions with seamless support.

West Japan Office
6F Midosuji Mitsui Bldg. 4-1-3 Bingo-machi, Chuo-ku, Osaka
+81-6-6121-2806

Pharmaceuticals and Medical Devices Agency (PMDA), Kansai Branch

To help academia and venture companies create innovative drugs, etc. in Japan, the PMDA Kansai Branch conducts Regulatory Science (RS) General Consultations and RS Strategy Consultations for designing both non-clinical trial plans and clinical trial plans required in the early phase of development. PMDA also provides face-to-face consultation regarding clinical trials and application materials. PMDA undertakes inspections whether facilities and control procedures for manufacturing medicinal chemicals comply with GMP, etc.

Nakanoshima Qross Future Medical R&D Center 6F
4-3-51 Nakanoshima, Kita-ku, Osaka-shi, Osaka
+81-6-6448-8540

OSAKA BIO
HEADQUARTERS

Osaka Bio Headquarters Secretariat

(Life Sciences Industry Division, Osaka Prefectural Government)
25F Sakishima Building, 1-14-16 Nankokita, Suminoe-ku, Osaka City 559-8555 Japan

Phone +81-6-6210-9818
Fax +81-6-6210-9296
Web https://osaka-bio.jp/en
E-mail life-science@sbox.pref.osaka.lg.jp